Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.

× No keyword cloud information.

18 in total

1. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.

Authors: Lingling Shen; Jianhua Shen; Xiaomin Luo; Feng Cheng; Yechun Xu; Kaixian Chen; Edward Arnold; Jianping Ding; Hualiang Jiang
Journal: Biophys J Date: 2003-06 Impact factor: 4.033

2. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Authors: Atsuko Hachiya; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Xiongying Tu; Krzysztof Palczewski; Yee Tsuey Ong; Zhe Li; Daniel T Griffin; Matthew M Schuckmann; Junko Tanuma; Shinichi Oka; Kamalendra Singh; Eiichi N Kodama; Stefan G Sarafianos
Journal: J Biol Chem Date: 2012-07-02 Impact factor: 5.157

3. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.

Authors: Gabriela Barreiro; Cristiano R W Guimarães; Ivan Tubert-Brohman; Theresa M Lyons; Julian Tirado-Rives; William L Jorgensen
Journal: J Chem Inf Model Date: 2007-10-20 Impact factor: 4.956

4. Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).

Authors: Lan Xie; Huan-Fang Guo; Hong Lu; Xiao-Mei Zhuang; An-Ming Zhang; Gang Wu; Jin-Xiu Ruan; Ting Zhou; Donglei Yu; Keduo Qian; Kuo-Hsiung Lee; Shibo Jiang
Journal: J Med Chem Date: 2008-12-25 Impact factor: 7.446

5. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.

Authors: R W Buckheit; K Watson; V Fliakas-Boltz; J Russell; T L Loftus; M C Osterling; J A Turpin; L A Pallansch; E L White; J W Lee; S H Lee; J W Oh; H S Kwon; S G Chung; E H Cho
Journal: Antimicrob Agents Chemother Date: 2001-02 Impact factor: 5.191

6. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Authors: L M Demeter; R W Shafer; P M Meehan; J Holden-Wiltse; M A Fischl; W W Freimuth; M F Para; R C Reichman
Journal: Antimicrob Agents Chemother Date: 2000-03 Impact factor: 5.191

7. Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases.

Authors: S Loya; A Rudi; Y Kashman; A Hizi
Journal: Biochem J Date: 1999-11-15 Impact factor: 3.857

8. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.

Authors: Jinfeng Liu; Xiao He; John Z H Zhang
Journal: J Mol Model Date: 2014-09-20 Impact factor: 1.810

9. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.

Authors: M Witvrouw; M E Arranz; C Pannecouque; R Declercq; H Jonckheere; J C Schmit; A M Vandamme; J A Diaz; S T Ingate; J Desmyter; R Esnouf; L Van Meervelt; S Vega; J Balzarini; E De Clercq
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

10. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Authors: Fenglei Huang; Kristin Drda; Thomas R MacGregor; Joseph Scherer; Lois Rowland; Thuy Nguyen; Charles Ballow; Mark Castles; Patrick Robinson
Journal: Antimicrob Agents Chemother Date: 2008-10-27 Impact factor: 5.191